PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.
The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.
PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
The user experienced significant hair regrowth using finasteride, minoxidil, and other treatments but faced side effects like reduced libido and erectile issues. They are considering switching to Adgain Plus to improve hair health without affecting sexual health.
A user shared their positive experience with MoriTint, a Korean scalp micro pigmentation technique that enhances the appearance of hair density without being permanent. They now offer this service in Los Angeles and emphasize its benefits for those with thinning hair, while clarifying it is not suitable for those with significant hair loss or baldness.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
The user showed a one-year hair regrowth progress using finasteride only, after stopping minoxidil due to its toxicity to cats. They noticed hair growth around six or seven months into treatment.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
The user experienced better hair thickening results with a combination pill of oral minoxidil (3mg) and finasteride (1mg) compared to previous treatments with topical minoxidil and finasteride alone. They reported no significant side effects and expressed regret for not starting this treatment earlier.
A 27-year-old male experiencing hair loss post-Covid is considering PRP (platelet-rich plasma) therapy. He's seeking personal experiences about the process, particularly regarding pain levels, despite his dermatologist's assurance of using local anesthesia.
The user shared progress pictures showing significant hair regrowth using Minoxidil and a dermapen, expressing concerns about potential side effects of finasteride due to low testosterone levels. Another user reported increased testosterone and no side effects from finasteride, with improved libido.
PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.
The conversation is about using topical melatonin or zix for hair loss without affecting hormones. The user is seeking advice on which treatment is more effective.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.
Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.
The user experienced heart palpitations from using Fin (0.1%) and Min (10%) and is seeking alternatives. Options suggested include PRP or Mesotherapy, with a recommendation to try topical Fin without Min.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
A 29-year-old shares progress on hair recovery using a daily liposomal topical mix of finasteride and minoxidil, iRestore device, and several vitamins. They report no side effects from the topical treatment, unlike previous issues with oral finasteride.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.